Using phenytoin as a model analyte, we demonstrate an electrochemical enzyme immunoassay based on flowinjection analysis and incorporating 2,6-dichloroindophenol (DCIP) as a redox coupling agent. DCIP reacts with NADH to form NAD and DCIPH2, the reduced form of the coupling agent. The production of DCIPH2 is monitored at +250 mV vs Ag/AgCI. This low applied potential improves selectivity in the biologicalmatrix, differentiating against components that are oxidizable at the morepositive potentials required for direct electrochemical detection of NADH. The kinetics-based assay also eliminates other common interferences, mainly from ascorbic acid and glutathione. This system does not require precolumns or analytical columns for isolation of the NADH response. Good agreement with a routine clinical laboratory procedure for phenytoin is obtained for clinical samples (r = 0.95), illustrating the feasibility of such an approach. Electrochemically based detection methods are affected by none of the disadvantages that limit their optically based counterparts, while retaining similar or better detection limits. In earlier work with phenytoin, Eggers et al. (4) and Wright (5) successfullyadapted the EMIT assay to electrochemical techniques by using chromatographic separation and amperometric detection of NADH. The detection limits of these methods approached submilligrams per liter or less. Unfortunately, however, these methods are somewhat complicated, and because of the chromatographic step cannot be considered truly homogeneous. First, direct electrochemical oxidation of NADH occurs only at high potentials, which considerably decreasesthe selectivity of analyte detection in solutions that contain other electroactive compounds.Therefore, in those methods an analytical column was necessary to isolate the NADH response. Secondly, a precolumn was needed to prevent proteins in the sample from adsorbing to the electrode surface and attenuating the analytical signal.
advantages as FPIA. Although the EMIT assay can detect subnanomolar concentrations of analyte, it is limited by the detection limit of spectrophotometric detection (3), and is also subject to interference from hemolyzed, lipemic, and icteric samples.
Electrochemically based detection methods are affected by none of the disadvantages that limit their optically based counterparts, while retaining similar or better detection limits. In earlier work with phenytoin, Eggers et al. (4) and Wright (5) successfullyadapted the EMIT assay to electrochemical techniques by using chromatographic separation and amperometric detection of NADH. The detection limits of these methods approached submilligrams per liter or less. Unfortunately, however, these methods are somewhat complicated, and because of the chromatographic step cannot be considered truly homogeneous. First, direct electrochemical oxidation of NADH occurs only at high potentials, which considerably decreasesthe selectivity of analyte detection in solutions that contain other electroactive compounds.Therefore, in those methods an analytical column was necessary to isolate the NADH response. Secondly, a precolumn was needed to prevent proteins in the sample from adsorbing to the electrode surface and attenuating the analytical signal.
The aim of the present work was to evaluate as a model assay an improved electrochemical method having increased selectivity and requiring less costly instrumentation. We describe a simplified, homogeneous assay based on the reaction of NADH with 2,6-dichloroindophenol (DCIP) and the subsequent assay of the reduced product DCIPH2 by flow-injection analysis with electrochemical detection (FIAEc) . We also describe assay of clinical serum samples by the modified procedure and compare the results with results of FPIA assays of the same specimens.
MaterIals and Methods
Apparatus. For electrochemical analyses we used "BAS" flow-amperometric equipment (Bioanalytical Systems Inc., West Lafayette, IN 47906) with a 20-/.LL injection loop as described elsewhere (6). The amperometer was a BAS Model LC-4B. The electrochemical cell was a 12.7-zm (0.5 mil) thick thin-layer cell with a glassy carbon working electrode, an Ag/AgC1 reference electrode (3 mollL KCI), and a stainless steel auxiliary electrode. All potentials are reported vs Ag/AgC1 (3 mol/L KC1).
For sample handling we used a Fisher Model 1500 
Phenytoin immunoassay.
This homogeneous enzyme immunoassay for phenytoin is a sequential saturation method (7) performed at room temperature. We used a two-point kinetic method, sampling the enzyme reaction at 1 and 5 mm; the difference in responses at the two times reflects the rate of NADH production for a given phenytoin concentration. For convenience, but not from necessity, we processed each calibrator or unknown in its entirety before assaying the next.
Assays were performed according to the manufacturer's instructions (8) except that the reaction mixture was not aspirated into the spectrophotometer flow cell. Instead, we added two portions of the reaction mixture to separate aliquots of a DCII' solution at a timed interval and allowed the redox reaction to proceed for a known time. Thus, at 1 and 5 mm after the addition of Reagent B (enzyme-labeled phenytoin), 50 L of the reaction mixture and 250 L of pH 7.0 phosphate buffer were added to 300 L of 0.42 mmol/L DCIP solution. We determined the rate of NADH production by injecting this reaction mixture, after 5 mm, into the flow-injection analysis system for amperometric detection of DCIPH2. Calibrators were assayed three times, unknowns once. Each assay took 11 mm.
Results and DIscussIon

Determination of NADH by Use of DCIP
We have previously demonstrated that the redox coupling agent DCIP can be used to facilitate the electron transfer processinvolving NADH and is useflil for the analytical determination of NADH (9). The principle of the method is based on the reaction
Because the electrochemical oxidation potential of DCIPH2 is less positive than that of NADH, NADH can be indirectly quantified electrochemically at potentials less positive than that required for its direct oxidation. We chosea potential of +250 mV for this study. At this low potential, interferences from other substances commonly present in serum (e.g., antibody, other proteins, ascorbic acid, uric acid, and acetaminophen, which are oxidizable at the more extreme potential) are mostly avoided, as described elsewhere (9).
A calibration curve for NADH ( 
Stabilityof the ElectrodeResponse
Solid electrodes are well known to be susceptible to poisoning by sample components as well as by the products of electrochemical reactions (10, 11) . This is particularly true in complex biological matrices (such as whole blood, serum, plasma, urine), which contain a variety of proteins and other components that adsorb strongly to the electrode surface. Moreover, in repetitive sampling methods, the extent of electrode passivation may increase with the rate of sampling because the length of time available for electrode recovery between samples shortens (12) .
Successwith electrochemical detection therefore requires avoiding protein adsorption on the electrode. Various strategies have been adopted to protect the electrode surface (13) (14) (15) . The approach we used was to clean the electrode by the continuous flow in FIAEC. A high flow rate (1.0 mJ.Jmin or above) not only shortens the wash time and reduces sample dispersion, but also decreasesthe contact time between the sample solution and the electrode (16) . We also used a carrier of 0.1 mol/L phosphate buffer to improve the efficiency of washing (14) at a flow rate of 1.0 mL/min.
We estimated the successof this simple procedure by using a solution of bovine serum albumin as an interferent in testing the electrode responsefor the oxidation of ferrocyanide. In Figure 2 , peaks a are representative of 10 repetitive injections of only ferrocyanide. The responseshave a coefficient of variation (CV) of 2.5%. Peaks b show part of the result of having the albumin present with the ferrocyanide. After 12 injections, at a sample spacing of 2 mm, 40% of the response is lost becauseof electrode fouling from bovine serum albumin adsorbed on the electrode. Increasing the sample spacing to 3 mm (Figure 2d, or longer, c) , under otherwise the same conditions, preserves the response for more than 30 injections (CV= 3.7%, n= 33). Consequently, we chose a sample spacing of 4 mm for the assay. This, 
Determinationof Enzyme-ProducedNADH in the Biological Matrix
The reaction of DCIP with NADH in a matrix containing common redox interferents present in serum has been described previously (9) . In the present work, we allowed the NADH generated by glucose-6-phosphate dehydrogenase (G6PDH) to react with DCIP in a similar matrix, and studied the kinetics of NADH production.
We added 100 pL of substrate solution (glucose 6-phosphate and NADI and 100 pL of "biological" matrix (per liter, 500 mol of uric acid, 90 p.mol of ascorbic acid, 200 mmol of acetaminophen, 1.0 mol of glutathione, 12 mg of cytochrome c, and 3.0 mmol of hemoglobin) to 1.5 mL of 2.5 mmol/L DCII' solution. Different amounts of the EMIT kit G6PDH-containing Reagent B (20, 50, and 100 pL) and phosphate buffer were then added to bring the final volume to 1.8 mL. We estimated the concentrations of enzyme label from the technical information provided by Syva Co. We injected 20 j.L of the reaction mixture at timed intervals and determined the production rates of NADH. Figure 3 shows the rate of production of NADH vs G6PDH-labeled phenytoin concentration. As expected, the production rate increases with increased G6PDH concentration. The production rate with no enzyme present is due to the residual NADH in the solution. The plot of results for duplicate runs is linear (r = 0.999). The results indicate that the detection of NADH produced from the enzyme is easily monitored by this method without any interference from the synthetic matrix.
HomogeneousEnzyme Immunoassay
The EMIT phenytoin assay dependson the competition of phenytoin and G6PDH-labeled phenytoin for a limited amount of specificantibody. The unbound enzymelabeled phenytoin, in conjunction with G6P, converts NAD to NADH, while the bound enzyme is greatly inhibited.
As we have shown, the rate of DCIPH2 production in the NADH-DCIP reaction can be used to evaluate the concentration of phenytoin by using a two-point method to determine the rate. The advantage of using the reaction rate of the responseat a particular time is that it is not necessaryto know when the enzymatic reaction starts. Thus, a change in current response over a particular time frame can be taken at any time after the addition of Reagent B. Also, if ascorbic acid and glutathione are present in the serum sample, their contribution to the overall current response is cancelled by using the rate method (9). The approach I describe to using DNA probes in diagnostic tests is simpler than most existing formats. DNA in a sample is labeled by chemical reaction with bisulfite and methylamine to generate a sulfonated derivative. The DNA need not be purified to do this. The labeled sample is then incubated with an unlabeled, purified probe DNA, which is immobilized to a solid support. The amount of label remaining on the solid support after washing is detected by a monoclonal antibody that recognizes modified cytosines. The intensity of the signal depends on the amount of target DNA in the sample. Detection limits depend on the amount of immobilized DNA and on the degree of physical entrapment of the labeled DNA in sample material, but can be as low as 5 pg. This format is well suited to automation for use with existing robotic enzyme immunoassay procedures.
AddItIonalKeyphrases: immunoassay robotics
For some diagnoses, tests based on DNA probes have substantial advantages of speed, specificity, and sensitivity over other tests (1). Several tests involving DNA probes to detect infectious disease agents have been described(2-5). However, these require a complex series of manipulations, and so are poorly suited to routine clinical use (1,6). Automation could avoid this problem, but the complexity of the tests requires that a robot be programmed (or built) specifically to deal with DNA probe tests. This problem of complexity has limited the use of probe tests in clinical settings.
